We have proposed that these pro-angiogenic activities of iodothyronines based at αvβ3 may limit the effectiveness of anti-angiogenic therapy in cancer patients [14, 18], and we have shown in vascularization models such as the chick chorioallantoic membrane (CAM) [18] that pharmacologic or immunologic inhibition of thyroid hormone action at αvβ3 profoundly reduces angiogenic activity of the hormone. The gene discussed is TG; the disease is cancer.